secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-08-31T19:54:51+00:00
Accession:  0001140361-26-035055
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio announces voluntary U.S. government agreement to expand Medicaid access, avoid pricing mandates
--------------------------------------------------------------------------------

- Voluntary agreement with U.S. government expands Medicaid access to Attruby via GENEROUS Model; specific terms confidential.
- BridgeBio expects no future pricing mandates; pricing commitments exclude medicines approved exclusively for orphan indications.
- CEO Neil Kumar joined President Trump at White House to announce deal; no impact on ForgingBridges copay program ($0/mo for qualifying patients).
- Three drugs under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), infigratinib for achondroplasia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/0001140361-26-035055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036126035055/ef20081330_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-035055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer